Caremark will sell a genetically engineered drug.
Within two weeks, the Newport Beach health-care company will begin dispensing its new drug Protropin, a human growth hormone made by Genentech of South San Francisco. The drug is used to treat dwarfism, a condition affecting up to 15,000 children. Under the agreement, Caremark will distribute Protropin nationwide to patients not served by hospital pharmacies; Genentech sells directly to the hospital pharmacies. Last week, Protropin became the second biotechnology drug to receive Food and Drug Administration approval for sale in the United States.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
